Last updated March 2, 2026
Supplement Review
Medium Chain Triglycerides (MCT)
for Cognitive Function in Dogs
Supplementation with MCT in the early phases of cognitive dysfunction may reduce the rate of cognitive decline and result in mild improvements in cognition, though evidence is limited.
Prepared by the Pet Evidence Project editorial team.
Evidence grade
Moderate Evidence
Studies evaluated diets and had a moderate-high risk of bias
About our grading systemEvidence Snapshot
-
Best supported for
Cognitive function
-
Evidence quality
Low
-
Amount of research
Moderate
-
Safety
Low risk
-
Observed benefit
Moderate Evidence
Evaluated for dogs across 6 peer-reviewed references.
Evidence Review (Deep Dive)
Explore the science behind the evidence. Each section expands to reveal the full review.
Does supplementation with medium chain triglycerides (MCT) improve signs of cognition in adult dogs with signs of early cognitive dysfunction?
Full scientific review The full scientific review, including evidence, safety, and practical context.
Medium-chain triglycerides (MCTs) may serve as an alternative energy substrate for the aging canine brain. With cognitive dysfunction, or age-related mental decline, glucose is not able to be utilized as effectively by cells within the brain. As glucose utilization declines, this can create a deficit in energy available to neurons. However, these cells are also able to utilize ketones as an alternate energy source, and this pathway appears to remain intact. MCTs are able to bypass traditional long-chain fatty acid pathways by being transported directly to the liver. There, they undergo rapid hepatic β-oxidation to produce ketone bodies like β-hydroxybutyrate (βHB), which cross the blood-brain barrier to provide a secondary fuel source.
Beyond simple energetics, MCT metabolites may exert direct neuroprotective effects by modulating neurotransmission and supporting antioxidant responses.
Pharmacologically, MCT supplementation is distinguished by its ability to induce intermittent ketosis even in a well-fed state, unlike the strict carbohydrate restriction required for a traditional ketogenic diet. Clinical evidence in aged Beagle dogs and those with Canine Cognitive Dysfunction (CCD) have demonstrated that diets supplemented with 5.5% to 9% MCT can improve visuospatial function, learning, and attention. Interestingly, these procognitive benefits have been observed even when plasma βHB levels remain relatively low (0.3–0.6 mM), suggesting that the therapeutic effect may be mediated by direct actions of medium-chain fatty acids (MCFAs) in the brain or specific regional increases in ketone utilization rather than high systemic ketosis alone. MCTs are generally considered safe and are likely to be most effective when initiated during the early stages of cognitive impairment to support neuronal health before irreversible damage occurs.
There also appears to be a mild effect on palatability with some dogs, though this was most often seen at higher percentages of MCT in the diet (>6%).
Currently, supplementation appears to be primarily achieved through prescription diets and to a lesser degree supplements.
The Bottom Line
Multiple studies evaluated the effects of MCT supplemented diets and found consistent mild positive results. However, these studies were largely funded by manufacturers with related products, imparting a moderate-high risk of bias. While this leads to caution with interpretation of results, there are parallel studies that demonstrate improved cognitive effect in dogs with epileptic seizures, which may signify a greater likelihood of efficacy (although results are not directly translatable).
Compare Medium Chain Triglycerides Products
We evaluate the science first, then help you check product quality and transparency.
No matched products are published yet
Product matches appear here only after our editorial team verifies their ingredient and quality details.
Key References
6 peer-reviewed studies- 1
Pan Y, Landsberg G, Mougeot I, et al.. Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study. (opens in a new tab) . Front Nutr. (2018).
-
Evidence first
We evaluate ingredients based on the quality and consistency of scientific evidence.
-
Veterinarian-authored
Content is written or reviewed by board-certified veterinary professionals.
-
Independent
No industry funding, sponsorships, or advertising influence our conclusions.